Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Allogene Therapeutics Inc’s stock clocked out at $2.60, down -8.45% from its previous closing price of $2.84. In other words, the price has decreased by -$8.45 from its previous closing price. On the day, 27.08 million shares were traded.
Ratios:
To gain a deeper understanding of ALLO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.35 and its Current Ratio is at 9.35. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when MESSEMER DEBORAH M. bought 13,313 shares for $2.43 per share.
Douglas Earl Martin sold 6,404 shares of ALLO for $10,951 on Feb 03 ’25. The SVP, General Counsel now owns 587,848 shares after completing the transaction at $1.71 per share. On Feb 03 ’25, another insider, Parker Geoffrey M., who serves as the CHIEF FINANCIAL OFFICER of the company, sold 4,361 shares for $1.73 each. As a result, the insider received 7,545 and left with 1,301,540 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 13628.71 while its Price-to-Book (P/B) ratio in mrq is 1.17.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $5.78, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is 32.48%, while the 200-Day Moving Average is calculated to be 5.45%.
Shares Statistics:
A total of 209.50M shares are outstanding, with a floating share count of 138.14M. Insiders hold about 34.11% of the company’s shares, while institutions hold 65.95% stake in the company.
